Rapport Therapeutics (NASDAQ:RAPP) Stock: Insider Ramiro Sanchez Acquires 3,600 Shares

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Director Ramiro Sanchez bought 3,600 shares of the company’s stock in a transaction on Friday, October 23rd. The stock was bought at an average price of $27.35 per share, for a total transaction of $98,460.00. Following the completion of the purchase, the director owned 3,600 shares of the company’s stock, valued at approximately $98,460. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Rapport Therapeutics Stock Down 2.3%

Rapport Therapeutics stock opened at $25.93 on Friday. Rapport Therapeutics, Inc. has a twelve month low of $23.75 and a twelve month high of $52.93. The firm has a 50 day moving average price of $39.01 and a 200-day moving average price of $38.93. The company has a market capitalization of $1.24 billion, a P/E ratio of -8.53 and a beta of 1.22.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.07). Equities analysts expect that Rapport Therapeutics, Inc. will post -4.08 EPS for the current fiscal year.

Key Headlines Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 met both Phase 2 endpoints in bipolar mania. The drug delivered statistically significant placebo-adjusted improvements in mania scores, and Rapport plans to advance it into Phase 3. Success could expand RAP-219’s opportunity beyond epilepsy and materially increase the company’s pipeline value. Rapport Therapeutics Phase 2 results
• Positive Sentiment: Analysts remain optimistic and raised price targets. JonesTrading lifted its target to $82, BTIG to $89 and Raymond James to $86, while HC Wainwright maintained a Buy rating. The reported consensus target of approximately $68.36 implies substantial upside from recent levels. Rapport Therapeutics analyst price target
• Positive Sentiment: Multiple insiders bought shares on the open market. CFO Troy Ignelzi purchased 5,500 shares, while directors Steven Paul, John Maraganore, Wendy Young, Paul Silva and Ramiro Sanchez also bought shares. The purchases totaled roughly $1.8 million based on the disclosed transactions and may signal management confidence following the clinical update. Rapport Therapeutics insider buying
• Neutral Sentiment: An analysis suggested Rapport could be significantly below estimated fair value following the Phase 2 results, but that valuation depends on successful Phase 3 development, regulatory approval and eventual commercialization.
• Negative Sentiment: Investors may have viewed the clinical win as less decisive than hoped. Reports indicated that some portions of the data only narrowly met expectations, potentially prompting profit-taking after the initial rally. Rapport bipolar mania data analysis
• Negative Sentiment: Rapport remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss missed analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. CEO Abraham Ceesay also sold 2,210 shares, a relatively small reduction of 0.49% in his holdings, which contrasts with the broader insider buying. SEC CEO ownership filing

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. JonesTrading lifted their price objective on Rapport Therapeutics from $50.00 to $82.00 and gave the stock a “buy” rating in a report on Wednesday. UBS Group initiated coverage on Rapport Therapeutics in a research report on Thursday, October 15th. They issued a “buy” rating and a $71.00 price objective on the stock. Raymond James Financial reiterated a “strong-buy” rating and set a $86.00 target price on shares of Rapport Therapeutics in a research report on Tuesday. BTIG Research raised their price target on Rapport Therapeutics from $75.00 to $89.00 and gave the company a “buy” rating in a research report on Tuesday, October 20th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Rapport Therapeutics in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $68.36.

Hedge Funds Weigh In On Rapport Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of RAPP. KBC Group NV purchased a new position in shares of Rapport Therapeutics in the first quarter worth $30,000. Sterling Capital Management LLC boosted its position in Rapport Therapeutics by 597.9% during the 3rd quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock valued at $33,000 after acquiring an additional 843 shares in the last quarter. State of Wyoming bought a new stake in shares of Rapport Therapeutics during the second quarter valued at approximately $65,000. Meeder Asset Management Inc. purchased a new stake in shares of Rapport Therapeutics in the 2nd quarter worth about $116,000. Finally, AlphaCentric Advisors LLC increased its stake in shares of Rapport Therapeutics by 6.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock worth $201,000 after acquiring an additional 408 shares in the last quarter.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.